Navigation Links
CareFusion Reports Second Quarter Fiscal 2011 Results
Date:2/3/2011

lion and $0.06, respectively. The results of the ISP operations have not been classified as discontinued operations in the accompanying financial tables as the criteria for this classification was not met in the second quarter of fiscal 2011. The divestiture is expected to close in April 2011, subject to customary closing conditions. The company will include the ISP results in discontinued operations beginning in the third quarter of fiscal 2011.

Second Quarter ResultsCareFusion's reported results compare to the three and six month periods ended Dec. 31, 2009.

The company reported revenue for the second quarter of fiscal 2011 of $1,002 million, compared to $1,019 million in the second quarter of fiscal 2010, a decrease of 2 percent on a reported basis or 1 percent on a constant currency basis after adjusting for an $8 million unfavorable foreign currency impact. The year-over-year decline was driven primarily by lower sales in the company's Respiratory business.

Operating income was $126 million, down 1 percent compared to $127 million in the prior year period. Excluding nonrecurring items, adjusted operating income for the second quarter increased to $155 million from $149 million.

Operating expenses, including selling, general and administrative (SG&A), research and development (R&D) and restructuring and acquisition integration charges in the second quarter totaled $349 million, or 35 percent of total revenue. Excluding nonrecurring items, adjusted operating expenses in the second quarter totaled $320 million, or 32 percent of total revenue. Adjusted SG&A expenses were $284 million and R&D investments totaled $36 million.

The company reported income from continuing operations in the second quarter of $76 million, or $0.34 per diluted share. Adjusted income from continuing operations was $98 million, or $0.44 per diluted share, and the adjusted tax rate was 26.8 percent for the second quarter.


'/>"/>

SOURCE CareFusion Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition
2. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
3. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
4. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
5. CareFusion Moves First Quarter Earnings Announcement to November 5
6. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
7. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
8. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
9. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
10. CareFusion Will Host an Earnings Conference Call on Feb. 9 to Discuss the Results for the Second Quarter of Fiscal 2010
11. FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets  has announced the addition of ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... needle commonly used with a syringe to inject substances ... it. A hypodermic needle is used for rapid delivery ... ingested. Hypodermic needles are broadly classified into non-safety and ...
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... September 30, 2011. "We are focused on ... complete response letter around year-end and filing the lorcaserin ... the first half of next year," stated Jack Lief, ...
... China Kanghui Holdings (NYSE: KH ) ("Kanghui" or ... orthopedic implants in China, today announced financial results for the ... Highlights Total net revenue for the third ... from RMB63.6 million in the corresponding period of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 7Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 8China Kanghui Holdings Reports Third Quarter 2011 Financial Results 2China Kanghui Holdings Reports Third Quarter 2011 Financial Results 3China Kanghui Holdings Reports Third Quarter 2011 Financial Results 4China Kanghui Holdings Reports Third Quarter 2011 Financial Results 5China Kanghui Holdings Reports Third Quarter 2011 Financial Results 6China Kanghui Holdings Reports Third Quarter 2011 Financial Results 7China Kanghui Holdings Reports Third Quarter 2011 Financial Results 8China Kanghui Holdings Reports Third Quarter 2011 Financial Results 9China Kanghui Holdings Reports Third Quarter 2011 Financial Results 10China Kanghui Holdings Reports Third Quarter 2011 Financial Results 11China Kanghui Holdings Reports Third Quarter 2011 Financial Results 12China Kanghui Holdings Reports Third Quarter 2011 Financial Results 13China Kanghui Holdings Reports Third Quarter 2011 Financial Results 14
(Date:7/13/2014)... treatment and variations in the quality of care are ... patients still varies widely between regions within Europe, according ... adults to date, published in The Lancet Oncology ... for most cancers of the blood has increased over ... of new targeted drugs in the early 2000s such ...
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... irrigation systems are mainly utilized for agriculture in order ... maintain soil quality. The application of micro irrigation systems ... generator for manufacturers in future. The trend of utilizing ... to the adoption of micro irrigation techniques for agriculture, ... for micro irrigation systems, as they reduce the overall ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... The federal court overseeing thousands of ... against Johnson & Johnson’s Ethicon, Inc. is preparing to ... to get underway next month. According to an Amended ... Southern District of West Virginia on July 9, 2014, ... 2014 at 3:00 p.m. July selection is slated to ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... an approved clot-busting drug remains the most beneficial proven ... ,The Guidelines for the Early Management ... options – such as intra-arterial administration of clot-busting drugs ... ,The guidelines focus on the crucial ...
... may hold the key to not only stopping heart ... ever occurring//. Researchers at Mount Sinai School of Medicine ... with a novel contrast agent know as N1177 can ... stroke. The findings may help physicians diagnosis a heart ...
... resistance after the failure of an anti-HIV drug combination is ... cell losses, according to a study of patients failing treatment ... the study also found that on average, patients who remained ... choice still available to them for every six months on ...
... special envoy for the fight against tuberculosis, on Tuesday called ... the spread of TB and HIV in Africa.// ... that the two diseases are spreading rapidly across the continent ... assistance. "We are providing antiretrovirals to as many people as ...
... has evolved to become resistant to all classes of antibiotics ... U.S. Centers for Disease Control and Prevention (CDC) has said ... due to the emergence of drug-resistant strains in ... remains as there is no indication so far that the ...
... - artificial legs made in Rajasthan - is all set to ... ,Experts from the Bhagwan Mahaveer Viklang Sahayta Samiti (BMVSS) ... Indian contingent of the UN peacekeeping force in Lebanon, BMVSS general ... a camp in Lebanon April 14 to 25. Five technicians would ...
Cached Medicine News:Health News:Intravenous Delivery of Clot-busting Drug Still Best Intervention for Ischemic Stroke 2Health News:CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 3Health News:Jaipur Foot Takes Off for Lebanon 2
Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium....
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
Curved shafts with serrated 1.5 mm upper and 2 mm lower jaws. Serrated cross action handle with slide lock and polished finish. Most popular size or model....
A gently curved forceps designed to easily fold today's soft intraocular lenses. The serrated handle ensures a firm grip throughout the folding procedure....
Medicine Products: